iX Biopharma Ltd

42C

Company Profile

  • Business description

    iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical; and Nutraceutical segments. The firm's business segments operate in the United States of America, Australia, China, Singapore and others, of which the majority of the revenue comes from the Australia. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

  • Contact

    1 Kim Seng Promenade
    No. 14-01
    Great World City East Lobby
    Singapore237994
    SGP

    T: +65 62352270

    https://www.ixbiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    30 June 2027

    Employees

    48

Stocks News & Analysis

stocks

Two ASX shares get takeover bids

Our take on the two bids.
stocks

Anthropic and OpenAI face commodification threats. Here’s what to watch for

Frontier AI labs face a three-pronged set of challenges.
stocks

Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment

We think it is a sign that the firm is finally moving out of its comfort zone to find places to put capital to work.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,975.7035.300.39%
CAC 407,868.0588.65-1.11%
DAX 4025,319.77302.84-1.18%
Dow JONES (US)51,966.0336.38-0.07%
FTSE 10010,764.69117.21-1.08%
HKSE24,186.83124.110.52%
NASDAQ26,430.89290.851.11%
Nikkei 22564,916.70407.59-0.62%
NZX 50 Index13,652.070.000.00%
S&P 5007,690.7331.290.41%
S&P/ASX 2008,845.7039.000.44%
SSE Composite Index3,716.288.810.24%

Market Movers